Business Context and Reporting Period
Company: BioNexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: BGLC operates in the biochemical industry through two Malaysian subsidiaries: MRNA Scientific (functional genomics for disease detection) and Chemrex Corporation (wholesaler of industrial chemicals). The company is a smaller reporting company and an emerging growth company listed on Nasdaq under the symbol BGLC.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $2,630,376 | $2,553,686 | $6,986,791 | $7,497,739 |
| Gross Profit | $326,536 | $354,332 | $980,287 | $1,062,943 |
| Gross Margin | 12.4% | 13.9% | 14.0% | 14.2% |
| Net Loss | $(1,345,370) | $(2,609,189) | $(1,250,023) | $(2,937,506) |
| EPS (Basic/Diluted) | $(0.017) | $(0.157) | $(0.023) | $(0.218) |
| Cash & Equivalents | $4,137,219 (as of Sept 30, 2024) | |||
| Working Capital | $5,635,310 (as of Sept 30, 2024) |
Segment Performance (YTD 2024): Chemrex contributed 99.8% of total revenue ($6.98M) and generated a net profit of $41,074. MRNA Scientific contributed 0.2% of revenue ($11,224) and reported a net loss of $(380,791).
Material Changes vs. Prior Period
- Revenue: Q3 2024 revenue increased 3.0% year-over-year, driven by a 3.6% increase in Chemrex sales. However, YTD revenue decreased 6.8% due to slower performance in the first two quarters.
- Profitability: Net loss improved significantly in Q3 2024 compared to Q3 2023 (down 48.4%), primarily due to a reduction in operating expenses and a significant foreign currency translation gain of $1.05M in Q3 2024 versus a loss of $18.6K in Q3 2023.
- Operating Expenses: Q3 operating expenses decreased 30.9% year-over-year to $2.13M, attributed to lower professional fees related to the 2023 Nasdaq listing and reduced share-based compensation.
- Cash Flow: Net cash used in operating activities increased to $2.16M for the nine months ended Sept 30, 2024, compared to $1.04M in the prior year period, despite the lower net loss, due to changes in working capital and inventory levels.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
The filing does not provide specific numerical financial guidance for the full year 2024. Management believes current cash flows are sufficient to sustain operations for at least the next 12 months.
Material Risks and Contingencies
- Nasdaq Delisting: On November 5, 2024, the company received notification of delisting from Nasdaq due to failure to maintain the $1.00 minimum bid price. The company has requested a hearing to appeal, which stays the suspension pending a decision. A reverse stock split is being considered as a corrective action.
- Audit Committee Investigations (Chemrex): The Audit Committee is investigating several irregular transactions at the Chemrex subsidiary, including:
- Property Sale: An offer to sell Chemrex's main operating premises for ~$1.07M entered into on Sept 30, 2024, potentially lacking proper authorization and arm's-length terms.
- Related Party Transactions: Purchases of materials (~$170k) from Honkuk Material Sdn. Bhd. (owned by directors) and payments to a director (~$43k) lacking documented board approval.
- Invalid Asset Purchase: A transaction for machinery and know-how (~$190k) with "Quote Me Sdn. Bhd.," which was subsequently determined to be a dissolved entity, raising concerns over the legitimacy of the asset.
- Unauthorized Remuneration: Substantial increases in director remuneration (~$917k) without documented approval.
- Internal Controls: Management acknowledged material weaknesses in internal controls over financial reporting at Chemrex, specifically regarding transaction authorization and related-party oversight. New protocols are being implemented.
Investor Verification Checklist
- Delisting Status: Verify the outcome of the Nasdaq hearing request and the timeline for potential delisting or implementation of a reverse stock split.
- Investigation Outcomes: Monitor updates on the Audit Committee's investigation into Chemrex transactions, specifically the potential rescission of the property sale and the validity of the machinery purchase from the dissolved entity.
- Related Party Governance: Confirm the implementation of new internal controls to prevent unauthorized related-party transactions and director remuneration increases.
- Cash Runway: Assess the sustainability of the $4.1M cash position given the continued operating losses and potential costs associated with the delisting appeal and investigations.
- Segment Viability: Evaluate the long-term viability of the MRNA Scientific segment, which reported minimal revenue and significant losses compared to the Chemrex segment.